Vertex Pharmaceuticals Incorporated Financial Analysis
Current Price: $479.62 -0.18%
Market Cap: $121.73B
Sector: Healthcare
P/E Ratio: 29.32
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older
Report Contents
- Income Statement Analysis (5-year history)
- Balance Sheet Overview
- Cash Flow Statement
- Key Financial Ratios
- Valuation Metrics (P/E, EV/EBITDA, P/S)
- Peer Comparison
- Revenue & Earnings Growth Trends
- Margin Analysis
- Analyst Price Targets
- DCF Valuation Model